Suppr超能文献

HLA-DR14 与日本自身免疫性肝炎患者治疗反应的相关性。

Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis.

机构信息

Department of Hepatology, Toranomon Hospital, Takatsu-ku, Kawasaki City, Japan.

出版信息

Dig Dis Sci. 2010 Jul;55(7):2070-6. doi: 10.1007/s10620-009-0995-x. Epub 2010 Jan 22.

Abstract

BACKGROUND

Influence of human lymphocyte antigen (HLA) on the therapeutic response in autoimmune hepatitis (AIH) is not known.

AIMS

To evaluate if HLA-DR types influence biological and histological responses to corticosteroids in patients with AIH.

METHODS

During 28 years from 1979 through 2007, 48 patients with definite diagnosis of AIH received long-term corticosteroid therapy (median 9 years [range: 5-28 years]) in a single Japanese center. They were followed for transaminase levels and received liver biopsy before and after the treatment.

RESULTS

DR4 was detected in 32 and DR14 in 11 patients; seven possessed both DR4 and DR14. DR4 was more frequent in AIH patients than in the general population (67% vs. 22%), while DR14 was comparably frequent between them (23% vs. 17%). Overall, biochemical response was achieved in 43 (90%) of the 48 patients. The sustained biochemical response to a maintenance prednisolone dose < 10 mg was gained more frequently in the patients with than without DR14 (10/11 [91%] vs. 10/37 [27%], P < 0.001). Marked histological improvement with a decrease in histology activity index (HAI) score by > 2 points was achieved in 31 of the 32 (97%) biochemical responders. Histological aggravation with an increase in HAI score occurred in 4 of the 16 (25%) patients without biochemical response (non-responders and relapsers combined), but in none of the 32 responders.

CONCLUSION

Long-term immunosuppressive treatment can improve the outcome of Japanese patients with AIH, and DR14 is associated with excellent biochemical response.

摘要

背景

人类淋巴细胞抗原(HLA)对自身免疫性肝炎(AIH)治疗反应的影响尚不清楚。

目的

评估 HLA-DR 型是否影响 AIH 患者对皮质类固醇的生物学和组织学反应。

方法

1979 年至 2007 年的 28 年间,在日本的一家中心,48 例明确诊断为 AIH 的患者接受了长期皮质类固醇治疗(中位数 9 年[范围:5-28 年])。在治疗前后,对他们进行了转氨酶水平的随访并进行了肝活检。

结果

32 例患者检测到 DR4,11 例患者检测到 DR14;7 例患者同时具有 DR4 和 DR14。DR4 在 AIH 患者中比在普通人群中更为常见(67%比 22%),而 DR14 在两者之间则较为常见(23%比 17%)。总体而言,48 例患者中有 43 例(90%)获得了生化应答。在维持泼尼松剂量<10mg 时,持续的生化应答在有和没有 DR14 的患者中更为常见(11/11[91%]比 10/37[27%],P<0.001)。在 32 例生化应答者中,31 例(97%)的组织学改善明显,组织学活动指数(HAI)评分下降>2 分。在没有生化应答(无应答和复发者合并)的 16 例患者中,有 4 例(25%)发生组织学加重,而在 32 例应答者中无 1 例发生。

结论

长期免疫抑制治疗可以改善日本 AIH 患者的预后,DR14 与良好的生化应答相关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验